A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells.

PinA1, a CK1α molecular glue degrader, preferentially degrades CK1α at nanomolar concentrations and activates p53 to drive apoptosis in TP53 wild-type AML cells.

• Why it matters: CK1α is an upstream regulator of the p53 pathway, and selective degradation could improve AML therapy while sparing normal hematopoietic cells.
• What they did: The study developed PinA1 and tested it in preclinical AML models, measuring CK1α degradation, p53 pathway activation, and viability in TP53 wild-type versus TP53 mutated AML cell lines and primary AML cells.
• The result: PinA1 induced CK1α degradation and p53-dependent apoptosis in TP53 wild-type primary AML cells, showed minimal effects on human peripheral blood and bone marrow mononuclear cells, and enhanced apoptosis with FLT3, BCL-2, or MDM2 inhibitors in xenografts.

AI summary of the abstract · may contain errors · not medical advice · read the paper.